|
1.
|
Payne MJ, Pratap SE and Middleton MR:
Temozolomide in the treatment of solid tumours: current results and
rationale for dosing/scheduling. Crit Rev Oncol Hematol.
53:241–252. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Gerson SL: MGMT: its role in cancer
aetiology and cancer therapeutics. Nat Rev. 4:296–307. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
O'Brien V and Brown R: Signalling cell
cycle arrest and cell death through the MMR System. Carcinogenesis.
27:682–692. 2006.PubMed/NCBI
|
|
4.
|
Roos WP, Batista LF, Naumann SC, et al:
Apoptosis in malignant glioma cells triggered by the
temozolomide-induced DNA lesion O6-methylguanine.
Oncogene. 26:186–197. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Newlands ES, Stevens MF, Wedge SR,
Wheelhouse RT and Brock C: Temozolomide: a review of its discovery,
chemical properties, pre-clinical development and clinical trials.
Cancer Treat Rev. 23:35–61. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Antonadou D, Paraskevaidis M, Sarris G, et
al: Phase II randomized trial of temozolomide and concurrent
radiotherapy in patients with brain metastases. J Clin Oncol.
20:3644–3650. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Chua SL, Rosenthal MA, Wong SS, et al:
Phase 2 study of temozolomide and Caelyx in patients with recurrent
glioblastoma multiforme. Neuro Oncology. 6:38–43. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Kerbel RS and Kamen BA: The
anti-angiogenic basis of metronomic chemotherapy. Nat Rev.
4:423–436. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Kim JT, Kim JS, Ko KW, et al: Metronomic
treatment of temozolomide inhibits tumor cell growth through
reduction of angiogenesis and augmentation of apoptosis in
orthotopic models of gliomas. Oncol Rep. 16:33–39. 2006.PubMed/NCBI
|
|
10.
|
Kong DS, Lee JI, Kim WS, et al: A pilot
study of metronomic temozolomide treatment in patients with
recurrent temozolomide-refractory glioblastoma. Oncol Rep.
16:1117–1121. 2006.PubMed/NCBI
|
|
11.
|
Kurzen H, Schmitt S, Naher H and Mohler T:
Inhibition of angiogenesis by non-toxic doses of temozolomide.
Anticancer Drugs. 14:515–522. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Fukushima T, Takeshima H and Kataoka H:
Anti-glioma therapy with temozolomide and status of the DNA-repair
gene MGMT. Anticancer Res. 29:4845–4854. 2009.PubMed/NCBI
|
|
13.
|
Natsume A, Ishii D, Wakabayashi T, et al:
IFN-beta down-regulates the expression of DNA repair gene MGMT and
sensitizes resistant glioma cells to temozolomide. Cancer Res.
65:7573–7579. 2005.PubMed/NCBI
|
|
14.
|
Hegi ME, Diserens AC, Gorlia T, et al:
MGMT gene silencing and benefit from temozolomide in glioblastoma.
N Eng J Med. 352:997–1003. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Chahal M, Xu Y, Lesniak D, et al: MGMT
modulates glioblastoma angiogenesis and response to the tyrosine
kinase inhibitor sunitinib. Neuro Oncology. 12:822–833. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Tolcher AW, Gerson SL, Denis L, et al:
Marked inactivation of O6-alkylguanine-DNA
alkyltransferase activity with protracted temozolomide schedules.
Br J Cancer. 88:1004–1011. 2003.
|
|
17.
|
Curran WJ Jr, Scott CB, Horton J, et al:
Recursive partitioning analysis of prognostic factors in three
Radiation Therapy Oncology Group malignant glioma trials. J Nat
Cancer Inst. 85:704–710. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Boiardi A, Silvani A, Ciusani E, et al:
Fotemustine combined with procarbazine in recurrent malignant
gliomas: a phase I study with evaluation of lymphocyte
06-alkylguanine-DNA alkyltransferase activity. J
Neurooncol. 52:149–156. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Pieper RO, Futscher BW, Dong Q and
Erickson LC: Effects of streptozotocin/bis-chloroethylnitrosourea
combination therapy on O6-methylguanine DNA
methyltransferase activity and mRNA levels in HT-29 cells in vitro.
Cancer Res. 51:1581–1585. 1991.PubMed/NCBI
|
|
20.
|
Sanada M, Hidaka M, Takagi Y, et al: Modes
of actions of two types of anti-neoplastic drugs, dacarbazine and
ACNU, to induce apoptosis. Carcinogenesis. 28:2657–2663. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Hirata S, Matsubara T, Saura R, Tateishi H
and Hirohata K: Inhibition of in vitro vascular endothelial cell
proliferation and in vivo neovascularization by low-dose
methotrexate. Arthritis Rheum. 32:1065–1073. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Belotti D, Vergani V, Drudis T, et al: The
microtubule-affecting drug paclitaxel has antiangiogenic activity.
Clin Cancer Res. 2:1843–1849. 1996.PubMed/NCBI
|
|
23.
|
Vacca A, Iurlaro M, Ribatti D, et al:
Antiangiogenesis is produced by nontoxic doses of vinblastine.
Blood. 94:4143–4155. 1999.PubMed/NCBI
|
|
24.
|
Fujita K, Sano D, Kimura M, et al:
Anti-tumor effects of bevacizumab in combination with paclitaxel on
head and neck squamous cell carcinoma. Oncol Rep. 18:47–51.
2007.PubMed/NCBI
|
|
25.
|
Lau DH, Duran GE, Lewis AD and Sikic BI:
Metabolic conversion of methoxymorpholinyl doxorubicin: from a DNA
strand breaker to a DNA cross-linker. Br J Cancer. 70:79–84. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Bijman MN, van Nieuw Amerongen GP, Laurens
N, van Hinsbergh VW and Boven E: Microtubule-targeting agents
inhibit angiogenesis at subtoxic concentrations, a process
associated with inhibition of Rac1 and Cdc42 activity and changes
in the endothelial cytoskeleton. Mol Cancer Ther. 5:2348–2357.
2006. View Article : Google Scholar
|
|
27.
|
Mathieu V, De Neve N, Le Mercier M, et al:
Combining bevacizumab with temozolomide increases the antitumor
efficacy of temozolomide in a human glioblastoma orthotopic
xenograft model. Neoplasia. 10:1383–1392. 2008.PubMed/NCBI
|
|
28.
|
Lam T, Hetherington JW, Greenman J, Little
S and Maraveyas A: Metronomic chemotherapy dosing-schedules with
estramustine and temozolomide act synergistically with anti-VEGFR-2
antibody to cause inhibition of human umbical venous endothelial
cell growth. Acta Oncol. 46:1169–1177. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Park JA, Joe YA, Kim TG and Hong YK:
Potentiation of anti-glioma effect with combined temozolomide and
interferon-beta. Oncol Rep. 16:1253–1260. 2006.PubMed/NCBI
|
|
30.
|
Citron M, Decker R, Chen S, et al:
O6-methylguanine-DNA methyltransferase in human normal
and tumor tissue from brain, lung, and ovary. Cancer Res.
51:4131–4134. 1991.
|
|
31.
|
Povey AC, Hall CN, Cooper DP, O'Connor PJ
and Margison GP: Determinants of O(6)-alkylguanine-DNA
alkyltransferase activity in normal and tumour tissue from human
colon and rectum. Int J Cancer. 85:68–72. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Helmlinger G, Endo M, Ferrara N, Hlatky L
and Jain RK: Formation of endothelial cell networks. Nature.
405:139–141. 2000. View
Article : Google Scholar
|
